Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Core Viewpoint - Eledon Pharmaceuticals is actively participating in the healthcare sector by presenting at the Piper Sandler Healthcare Conference, highlighting its commitment to engaging with investors and stakeholders [1]. Group 1: Company Overview - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [2]. - The company's lead investigational product is tegoprubart, an anti-CD40L antibody that targets the CD40 Ligand, which has significant therapeutic potential [2]. - Eledon is conducting preclinical and clinical studies in areas such as kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [2]. Group 2: Upcoming Events - David-Alexandre C. Gros, M.D., the CEO of Eledon, will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on December 4, 2025, at 8:50 a.m. ET [1]. - A webcast replay of the fireside chat will be available on the company's website following the live session [1].